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Abstract
Background: Coronary artery disease (CAD) has turned into a prevalent cause of morbi-
-mortality contributing some polymorphisms in the recurrence of major adverse cardiac events 
(MACE).
Methods: Three hundred and fifty six patients with first myocardial infarction (MI) were fol-
lowed up during a 60-month period to find out if ACE I/D, AT1R A1166C, PAI-I 4G/5G and 
GPIIIa a1/a2 polymorphisms, in combination with other classical cardiovascular risk factors, 
can contribute to the relapse of MACE.
Results: Two hundred and eighty five (80.1%) men and 71 (19.9%) women were followed 
up after first MI. The primary clinical endpoint, a composite of MACE, was reached in  
106 (29.8%) patients. In the Cox univariate survival analysis those risk factors influencing  
a poorer prognosis were age (p = 0.004), a positive family history of CAD (p = 0.007), diabetes 
(p = 0.004), smoking (p = 0.024), fibrinolytic therapy (p = 0.012) and having 2 or 3 vessels 
CAD (p = 0.046). Cox proportional hazards regression model showed that patients with the 
DD genotype had a 1.5 increased risk of having an unfavorable outcome when compared with 
No-DD genotype patients (RR 1.561, 95% CI 1.048–2.326, p = 0.028) and that patients with 
the ACE DD genotype plus the AT1R No-AA genotype, the GPIIIa No-a1a1 genotype or a com-
bination of both, had a twice higher risk than any other genotype of MACE in the follow-up 
(RR 1.978, 95% CI 1.286–3.043, p = 0.002).
Conclusions: Patients with the ACE DD genotype plus 1 or 2 unfavorable genotypes, the 
AT1R No-AA, the GPIIIa No-a1a1 or a combination of both, have twice higher the risk of 
MACE during their clinical follow-up. (Cardiol J 2014; 21, 3: 229–237)
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Introduction
Classical cardiovascular risk factors explain 
at most half of the cases of coronary events and 
therefore new factors are looked for in the area of 
the molecular genetics that may explain the diffe-
rence. Within it, polymorphisms, which scarcely 
alter the function of the codified protein, seem to 
promote an atherogenic effect contributing to the 
development of coronary heart disease [1].
The potential role of this study is to examine 
the relationship between polymorphisms (angioten-
sin-I converting enzyme [ACE] I/D, angiotensin 1 
receptor [AT1R] A1166C, plasminogen activator 
inhibitor-1 [PAI-I] 4G/5G and glycoprotein IIIa 
[GPIIIa] a1/a2), classical cardiovascular risk factors 
and coronary angiographic data in the recurrence 
of a major adverse cardiac event (MACE) after first 
myocardial infarction (MI).
Methods
Three hundred and fifty six  surviving patients, 
admitted to the Cardiology Service of the Complejo 
Hospitalario Universitario Insular-Materno Infantil 
of Gran Canaria due to first MI, were prospectively 
followed up over a period of 60 months. The diag-
nosis of MI was performed according to the ACC/ 
/AHA guidelines for the management of patients 
with ST-elevation MI [2] and unstable angina/non 
ST-elevation MI [3]. Inclusion criterion was being 
older than 18 years old and exclusion criteria were 
having a systemic malignant disease, a terminal 
chronic illness or a previous MI, coronary artery 
bypass grafting or coronary angioplasty.
High blood pressure was defined as a repe-
atedly elevated systolic/diastolic blood pressure 
of 140/90 mm Hg or higher. Dyslipidemia was 
determined if total cholesterol concentration was 
above 240 mg/dL or the patient was under lipid-
-lowering treatment. Diabetes mellitus was defined 
as having a fasting plasma glucose level higher than 
126 mg/dL or if the patient was under insulin or 
oral hypoglycemic treatment. Meanwhile, obesity 
was characterized if the body mass index (BMI) 
was above 30 kg/m2. Left ventricle ejection fra-
ction (LVEF) was calculated by echocardiography 
with the Teichholz formula and/or by endocardial 
tracing of the LV area, in systole and diastole, 
with the Simpson’s EF method. Patients receiving 
fibrinolysis were treated with recombinant tissue 
plasminogen activator (rtPA). Patients were con-
sidered revascularized if they underwent percu-
taneous coronary intervention or coronary artery 
bypass surgery after the first MI. Coronary artery 
disease (CAD) was classified, by angiography, as 
non-significant if the lesion occupied less than 50% 
of the lumen of the coronary vessel, moderate if 
the lesion occupied 50–75% of the lumen of the 
coronary vessel and severe if it occupied more 
than 90% of the lumen. The lesion was considered 
diffuse when a long segment of the coronary artery 
was affected.
The primary clinical endpoint was the recur-
rence of MACE (acute MI, unstable angina, sudden 
cardiac death or ischemic heart failure) during 
a 60-month period of follow-up and the analysis 
was performed by citation, telephonic interview, 
review of medical records or death certificates. All 
the patients were Caucasian, and all of them gave 
informed consents to participate in the study. The 
protocol of the study was approved by the hospital’s 
Ethics Committee.
Polymorphisms and genetic analysis
ACE gene plays an important role in the 
renin–angiotensin–aldosterone system (RAAS). 
The insertion deletion (I/D) polymorphism in this 
gene refers to an Alu repetitive sequence 287 bp 
long, in intron 16, resulting in three genotypes, 
DD and II homozygotes and ID heterozygotes. The 
I/D polymorphism is reported to determine circu-
lating and tissue ACE levels, so that individuals 
homozygous for the D allele have higher tissue and 
plasma ACE concentrations than heterozygotes 
and II homozygotes [4]. Therefore, patients with 
the ACE DD genotype are, theoretically, at an 
increased risk of MI.
ACE I/D polymorphism: Genomic DNA 
was obtained from peripheral leucocytes (300 μL 
of whole blood) and the ACE I/D polymorphism 
was determined by polymerase chain reactions 
(PCR). PCR was performed with sense primer 
5’ CTG GAG ACC ACT CCC ATC CTT TCT 3’ and 
antisense primer 5’ GAT GTG GCC ATC ACA TTC 
GTC AGA 3’ being he mutated oligonucleotide 
inserted into one of the two primers. The final 
volume of the mixture was 50 μL and contained 
0.76 μg DNA, 50 mM KCl, 10 mM Tris-HCl, pH 
8.3, 3 mM MgCl2, 0.5 mM dNTPs, 20 pM of each 
primer and 1 U Taq polymerase. PCR cycle was 
10 min of denaturation at 94oC, 30 cycles of 1 min 
each at 94oC denaturation, 58oC annealing, 72oC 
extension and 7 min of final extension at 72oC. The 
PCR products were separated on 2% agarose gel 
and visualized by ethidium bromide staining. The 
I allele produced a fragment in the 490-bp area 
and the D allele produced a fragment in the 190-bp 
area. The ID genotype showed 2 separate bands 
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in the 490 bp and in the 190 bp areas. To avoid 
the possibility of mistyping the ID heterozygotes 
as DD homozygotes, all DD genotypes were re-
-amplified by using a second primer pair specific 
for the inserted sequence [5].
AT1R A1166C polymorphism can potentially 
lead to RAAS activation; when the C allele is pre-
sent, AT1R density and sensitivity to angiotensin II 
increase. In fact, AT1R A1166C polymorphism, an 
adenine/cytosine base transversion at nucleotide 
position 1166, has been associated with ischemic 
heart disease and hypertension [6]. 
AT1R A1166C polymorphism: Genomic 
DNA was prepared from peripheral blood leuko-
cytes and PCR. ATR1 A1166C polymorphism 
(a single base substitution from A1166 to C1166) 
was carried out in a total volume of 50 μL con-
taining genomic DNA, 15 pmol of each primer, 
1X Taq polymerase buffer (1.5 mmol/L MgCl2), and 
1.2 U of ampliTaq DNA polymerase (Perkin Elmer, 
Foster City, CA, USA). The primers for ATR1 gene 
were forward 5’-TTG AGG TTG AGT GAC ATG 
TTC GA-3’ and backward 5’-CGG TTC AGT CCA 
CAT AAT GCA-3’. The PCR cycling conditions 
for A1166C were set as: 1 cycle at 94oC for 3 min, 
30 cycles at 95oC for 30 s, 55oC for 30 s, and 72oC 
for 60 s, and 1 final cycle of extension at 72oC for 
10 min. The reaction was then incubated for 2 h 
at 37oC, and then 10 μL of the digested products 
were loaded into a 3% agarose gel with ethidium 
bromide staining and separated by electrophoresis. 
The A1166C polymorphism of ATR1 was cate-
gorized as divisible homozygotes (CC), indivisible 
homozygotes (AA), and heterozygotes (AC) [7].
The 4G/5G I/D polymorphism (4 or 5 sequen-
tial guanosines, respectively) of PAI-1 is a major 
inhibitor of fibrinolysis. The polymorphism is loca-
ted in the gene promoter region (chromosome 7) 
and results in allele-specific responses to multiple 
agents. Accordingly, studies have shown the 4G 
allele to be associated with both higher levels of 
PAI-1 and cardiovascular risk [8].
PAI-1 4G/5G polymorphism: Genomic 
DNA was obtained from peripheral blood and 
genotyping of the 4G/5G polymorphism in the 
PAl-1 promoter region was performed by PCR 
using the following oligonucleotides: 5’-CACA-
GAGAGAGTCTGGCCACGT-3’ (sense) and 
5’ CCAACAGAGGACTCTTGGTCT-3’ (antisense). 
Reactions were performed in volumes of 50 μL 
with 0.06 mol of each oligonucleotide, 1.2 U of 
Taq DNA polymerase, 1.5 mmol of MgCl2 and 
0.1 mmol of each dNTP. The reaction conditions 
were as follows: initial denaturation at 95oC for 3 min 
followed by 30 cycles of denaturation at 95°C for 
30 s, alignment at 60°C for 30 s, and an extension 
step at 72°C for 30 s, followed by a final linear 
extension step at 72°C for 1 min. Amplification 
products of 99 bp (5G) and 98 bp (4G) were ob-
tained. The DNA fragments were separated by 
electrophoresis in 4% agarose gels and visualized 
using ethidium bromide [9].
The A1/A2 polymorphism of GPIIIa gene, 
caused by a thymine to cytosine nucleotide sub-
stitution at position 1565 that is associated with 
the occurrence of the amino acid leucine to proline 
variant at residue 33 of the mature protein, has 
been widely studied in cardiovascular diseases 
showing that possession of an A2 allele increases 
the risk for MI and CAD [10].
GPIIIa a1/a2 polymorphism: Genomic 
DNA was obtained from peripheral leucocytes 
and PCR was used to detect the GPIIIa a1/a1 
polymorphism using upstream primer 5’-TGGA-
CTTCTCTTTGGGCTCCTGACTTAC-3’ and the 
downstream primer 5’-CGATGGATTCTGGGCA-
CAGTTATC-3’. DNA was amplified for 37 cycles 
of denaturation at 96°C for 45 s, annealing at 57°C 
for 45 s, and extension at 72°C for 60 s. The final 
extension step was at 72°C for 4 min. The 266 bp-
-product was then incubated at 37°C for 1 h with 
10 U of MspI. The resulting fragments were then 
separated by size in a 2% agarose gel and visualized 
by ethidium bromide staining [11].
Statistical analysis
Quantitative variables were expressed as 
mean ± standard deviation or median and 5th and 
95th (5; 95) percentiles to describe a distribution 
of data. Qualitative variables were expressed as 
percentages. Possible associations between cate-
gorical variables were evaluated using the Pearson 
c2 test or Student’s t test for continuous data. The 
nonparametric Mann-Whitney U test was used 
to compare two independent samples when the 
assumption of normality or homogeneity of varian-
ce was not met. The Bonferroni correction was 
applied for adjusting statistical results for multiple 
comparisons. Table 1 shows the polymorphisms’ 
dichotomization with those favorable and unfavo-
rable genotypes.
Kaplan-Meier survival curves were used to 
estimate time-to-event and the log-rank test was 
used to compare Kaplan-Meier survival curves. 
Meanwhile, Cox proportional hazards regression 
model was used to assess the effect of multiple 
covariates on survival. The results were expressed 
as odds ratios (ORs) with their 95% confidence 
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intervals (CIs). Data analysis was carried out using 
SPSS 18.0 (SPSS, Chicago, IL, USA).
Results
Over a period of 60 (1;188) months, 285 (80.1%) 
men and 71 (19.9%) women aged between 18 and 
84 years old were followed up after hospital ad-
mission due to first MI. 181 (50.8%) patients were 
less than 55 years old and 175 (49.2%) patients 
were over 55 years old. 106 (29.8%) patients had 
events during the follow-up. 65 (18.3%) patients 
had unstable angina, 27 (7.6%) MI, 11 (3.1%) sud-
den cardiac death, 3 (0.8%) heart failure and 13 
(3.3%) patients death of non-cardiac origin. 237 
(66.6%) patients remained asymptomatic. Classical 
cardiovascular risk factors of the whole series and 
of the two subgroups of patients, patients with first 
MI below and above 55 years old, are summarized 
in Table 2. Meanwhile, genotype and alleles fre-
quencies, in the overall sample, are indicated in 
Table 3. Infarction location, fibrinolytic treatment, 
LVEF and coronary angiographic data are shown 
in Table 4.
Pearson c2 test evidenced no significant cor-
relation between ACE I/D, AT1R A1166C, PAI-1 
4G/5G and GPIIIa a1/a1 genotypic dichotomous 
variables and classical cardiovascular risk factors, 
even taken separately the early and late MI. The 
only polymorphism that reached statistical signifi-
cance was the AT1R A1166C polymorphism, when 
compared with having or not having hyperchole-
sterolemia, showing patients with dyslipidemia 
a higher incidence of AT1R AA genotypes (p = 0.017). 
Similarly, no association was seen between co-
ronary angiographic data and the four studied 
polymorphisms.
Meanwhile, in the long-rank test, those clas-
sical cardiovascular risk factors that influenced 
a poorer outcome were age (p = 0.004), having a fa-
mily history of coronary heart disease (p = 0.007), 
diabetes mellitus (p = 0.004), smoking (p = 0.024), 
being treated with fibrinolytic therapy (p = 0.012) 
and having 2 or 3 vessels CAD (p = 0.046). How-
ever, none of the studied polymorphisms influenced 
the prognosis in the univariate analysis.
Cox univariate analysis of the variables that 
influenced the clinical outcome and Cox proportio-
nal hazards regression model are shown in Tables 5 
and 6, respectively. Patients with the DD genotype 
had a 1.5 increased risk of having an unfavorable 
outcome when compared with No-DD patients 
(RR 1.561, 95% CI 1.048–2.326, p = 0.028). Similarly, 
patients with DD genotype plus the AT1R No-AA 
genotype, the GPIIIa No-a1a1 genotype or a combi-
nation of both, had twice more risk than any other 
genotype of presenting a MACE in the follow-up 
(RR 1.978, 95% CI 1.286–3.043, p = 0.002).
Discussion
Atherosclerosis in general, and coronary heart 
disease in particular, has become a prevalent cause of 
Table 1. Dichotomization of the polymorphisms in unfavorable and favorable genotypes.
Unfavorable genotypes Favorable genotypes 
ACE DD ACE II+ID
The DD genotype favors a higher production of ACE 
(50% higher than the II)
Lower production of ACE
Effect on endothelial proliferation and thrombosis Smaller effect on endothelial proliferation and thrombosis
AT1R AC+CC (No-AA) AT1R AA
Increased activity of the AT1R Decreased activity of the AT1R
Greater effect on cell proliferation and  
thrombosis caused by angiotensin II
Smaller effect on cell proliferation and  
thrombosis caused by angiotensin II
PAI-I 4GG+4G5G (No 5G5G) PAI-I 5G5G
The 4G4G has PAI concentrations 10–50%  
higher than the 5G5G
Lower PAI concentrations
Increased thrombogenic risk Low thrombogenic risk
GPIIIa No-a1a1 (a1a2+a2a2) GPIIIa a1a1
Increased activity of the GPIIb/IIIa receptor Decreased activity of the GPIIb/IIIa receptor
Increased platelet aggregation and thrombosis Lower platelet aggregability
ACE — angiotensin-I converting enzyme; AT1R — angiotensin II type 1 receptor; PAI — plasminogen activator inhibitor; GPIIIa — platelet gly-
coprotein IIIa [4, 6, 8, 10]
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morbi-mortality in the industrialized countries, due to 
a higher life expectancy and an inadequate diet habit 
and life style. Predisposing factors such as age, gender, 
BMI, hypertension, hypercholesterolemia, diabetes 
mellitus, smoking or a family history of cardiovascular 
disease are well known, however, they only explain half 
of the cases of coronary ischemic events. Therefore, 
new etiology factors in the genetic field are being inve-
stigated and many polymorphisms are being implicated 
in the physiopathology of the coronary events.
Cambien et al. [12] first demonstrated a po-
ssible role of the ACE DD genotype as a car-
diovascular risk factor. However, in subsequent 
years different studies have reached conflicting 
Table 2. Demographics data of all the patients and of the subgroups below and above 50 years of age.
Parameters Total AMI < 55 years AMI > 55 years P
Age 55.6 ± 13.2 44.7 ± 6.0 66.9 ± 7.9 0.000
Gender:
Male 285 (80.9%) 160 (56.1%) 125 (43.8%)
Female 71 (19.1%) 21 (29.5%) 50 (70.4%) 0.000
Family history:
No 289 (81.2%) 142 (78.5%) 147 (84.0%)
Yes 67 (18.8%) 39 (21.5%) 28 (16.0%) 0.229
Diabetes mellitus:
No 217 (61.0%) 126 (69.6%) 91 (52.0%)
Yes 139 (39.0%) 55 (30.4%) 84 (48.0%) 0.001
Arterial hypertension:
No 178 (50.0%) 112 (61.9%) 66 (37.7%)
Yes 178 (50.0%) 69 (38.1%) 109 (66.3%) 0.000
Smoker:
No smoker 114 (32.0%) 35 (19.3%) 79 (45.1%)
Ex smoker 79 (22.2%) 35 (19.3%) 44 (25.1%)
Smoker 163 (45.8%) 111 (61.3%) 52 (29.7%) 0.000
Dyslipidemia:
No 105 (29.5%) 39 (21.5%) 66 (37.7%)
Yes 251 (70.5%) 142 (78.5%) 109 (62.3%) 0.001
Obesity:
No (BMI < 30) 169 (69.8%) 103 (72.0%) 66 (66.7%)
Yes (BMI ≥ 30) 73 (30.2%) 40 (28.0%) 33 (33.3%) 0.453
Quantitative variables are expressed as mean ± standard deviation. Qualitative variables are expressed as percentages of total. The body 
mass index (BMI) was evaluated in only 242 patients (68%); AMI — acute myocardial infarction
Table 3. Genotype and allele polymorphism frequencies in the series.
Polymorphisms Genotype frequencies 
Number of cases (%)
Allele frequencies (%)
ACE II ID DD I D
57 (16.0) 171 (48.0) 128 (36.0) 40.0 60.0
AT1R AA AC CC A C
189 (53.1) 147 (41.3) 20 (5.6) 73.7 26.3
PAI-I 4G/4G 4G/5G 5G/5G 4G 5G
91 (25.6) 182 (51.1) 83 (23.3) 51.1 48.9
GPIIIa a1a1 a1a2 a2a2 a1 a2
233 (65.4) 112 (31.5) 11 (3.1) 81.2 18.8
Qualitative variables are expressed as percentages of total; ACE — angiotensin-I converting enzyme; AT1R — angiotensin II type 1 receptor; 
PAI-1 — plasminogen activator inhibitor; GPIIIa — platelet glycoprotein IIIa
www.cardiologyjournal.org 233
Efrén Martínez-Quintana et al., Prognostic value of polymorphisms in myocardial infarction
results. In this context, and as cornerstone in the 
literature reporting on the ACE ID polymorphi-
sm, Agerholm-Larsen et al. [13] demonstrated, in 
a meta-analyses of small and large studies that 
included a total of 32.715 white individuals, that 
plasma ACE activity was significantly increased 
for ACE ID and DD versus II patients, that blood 
pressure was not influenced by genotype, and that 
the risk of MI and ischemic heart disease was incre-
ased by 47% and 29%, respectively, for DD vs. ID 
and II genotypes in small studies but not in large 
researches. However, it should be emphasized that 
many patients included in the meta-analyses were 
under ACE-inhibitors or sartans which may have 
changed the results.
In relation to the clinical outcome after first 
MI, Ludwig et al. [14] showed (in patients who had 
Table 4. Clinical, echocardiographic and angio-
graphic data from the whole series.
Parameters Patients (%)
Infarction location:
Anterior 115 (32.3%)
Inferior 153 (43.0%)
Posterior 30 (8.4%)
Non Q wave 41 (11.5%)
Other locations 17 (4.8%)
Fibrinolysis:
No 196 (55.1%)
Yes 160 (44.9%)
LVEF:
< 40% 71 (20.0%)
≥ 40% 285 (80.0%)
Coronary arteries affected:
None 24 (10.8%)
One 106 (47.5%)
Two 53 (23.8%)
Three 40 (17.9%)
Coronarography severity:
None significant 40 (17.9%)
Moderate 23 (10.3%)
Severe 125 (56.1%)
Diffuse 10 (4.5%)
Severe and diffuse 7 (3.1%)
Total occlusion 18 (8.1%)
Revascularization:
No 111 (49.8%)
Yes* 112 (50.2%)
Qualitative variables are expressed as percentages of total. Of the 
356 patients enrolled in the study, 223 (62.6%) underwent catheteri-
zation, either during hospitalization or soon after hospital discharge. 
*Both percutaneous and surgical revascularization; LVEF — left 
ventricular ejection fraction
Table 5. Cox univariate analysis of the variables 
that influenced the clinical outcome.
Variable Relative risk  
(± 95% CI)
P
Age at infarction 1.021 (1.007–1.036) 0.004
Age at infarction:
Early infarction 1.000
Late infarction 1.576 (1.073–2.315) 0.020
Family history:
No 1.000
Yes 1.859 (1.189–2.906) 0.007
Diabetes mellitus:
No 1.000
Yes 1.758 (1.201–2.574) 0.004
Arterial hypertension:
No 1.000
Yes 1.417 (0.965–2.080) 0.076
Fibrinolysis:
No 1.000
Yes 0.599 (0.401–0.893) 0.012
ACE genotype:
No-DD 1.000
DD 1.419 (0.966–2.084) 0.074
Persistence of smoking:
No 1.000
Yes 2.051 (1.099–3.825) 0.024
Coronary artery disease:
None or one vessels 1.000
Two or three vessels 1.618 (1.009–2.596) 0.046
ACE — angiotensin-I converting enzyme; CI — confidence intervals
undergone coronary angiography either because of 
symptoms relating to CAD or unrelated conditions 
such as valvular disease) that the ACE D allele was 
associated with a greater risk of MI but not with the 
development of atherosclerosis. Likewise, Yoshida 
et al. [15], in a retrospectively study of 176 patients, 
suggested that the presence of the deletion allele of 
the ACE gene could be a risk factor for secondary 
cardiac events after MI. Also, Palmer et al. [16], in 
978 patients with MI and a mean age of 62.1 years, 
showed a strong association between the D allele 
and mortality over a mean of 2.6 years of follow-up. 
There were similar results in our series where the 
DD genotype led to a 1.5 increased risk of having an 
unfavorable outcome when compared with No-DD 
patients but without having a significant association 
with coronary angiographic data. This may sug-
gest, as stated by Ludwig et al. [14], that the risk 
of MI is influenced by 2 independent processes: 
atherogenesis that leads to coronary stenosis and 
the RAAS that appears to confer significant risk of 
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infarction by influencing the conversion to MI by 
rupture of the plaque surface.
However, the evidence is controversial and 
some authors have found no association between 
ACE I/D polymorphism and the increased risk of 
coronary events after first MI [17–19]. This may 
be due to the fact that, in the case of Franco et 
al. [17] the study population was under 45 years 
old, in the case of Andrikopoulos et al. [18] only 
in-hospital mortality was studied, and in the case 
of Keavney et al. [19] the only patients enrolled, 
who were subjected to fibrinolysis, had documen-
ted MI. Also, Arca et al. [20] in 394 consecutive 
patients who underwent coronary angiography of 
whom 21.5% had a history of MI, did not provide 
evidence of a significant association between the 
ACE genotypes and the conversion of coronary 
stenosis to MI. As well, Hanon et al. [21], in 1039 
consecutive white patients with symptomatic 
CAD who had successful percutaneous coronary 
intervention with stent implantation, found that 
the ACE I/D polymorphism did not influence the 
long term prognosis of these patients.
On the contrary, Tokunaga et al. [22], in 
a selected cohort of 441 Japanese patients with first 
MI, found an inverse relationship between the ACE 
DD genotype and the incidence of a new coronary 
event being the DD genotype associated with 
a significantly lower cardiac mortality. However, 
in this study the percentage of patients with the 
DD genotype was much lower than in our series 
and the follow-up period was considerably shorter.
Regarding the synergistic effect, between the 
ACE I/D and the AT1R A1166C polymorphisms, 
different studies have shown conflicting results. In 
this context, some authors [23–25] have found that 
subjects carrying the D allele of ACE gene and the 
C allele of AT1R gene had a higher risk of MI than 
those patients with the AT1R AA and the ACE II 
combined genotype. However, other authors have 
not found such synergic effect between both poly-
morphisms [26, 27].
In relation whether the above-mentioned poly-
morphisms are associated with an increased risk 
of MACE following an acute MI, Andrikopoulos et 
al. [18], in a multicenter and prospective study of 
1,603 consecutive patients with MI, showed and 
argued against a measurable effect of the ACE 
gene I/D polymorphism and A1166C polymorphi-
sm of the ATR1 gene on early prognosis after MI. 
However, these findings could be in relation to the 
low frequency of the C allele of AT1R genotype 
seen in their series.
In relation to the rest of polymorphisms, 
Margaglione et al. [28] in a cohort of 1,179 healthy 
employees found that the 4G/4G carriers exhibited 
a more frequent family history of CAD, supporting 
the hypothesis that the 4G variant was a transmis-
sible coronary risk factor. However, Panahloo et 
al. [29] found no evidence that subjects with the 
4G/4G polymorphism had higher PAI-1 levels on 
admission or 6 months after MI. Meanwhile, Bray 
et al. [30] showed that the GPIIIa a1/a2 genotype 
was associated with an excess of recurrent corona-
ry events in patients after MI who did not receive 
statins and that the ACE DD genotype added to 
this risk. Similarly, in our series, those patients 
with the ACE DD genotype and at least one or 
two theoretically unfavorable genotypes, the AT1R 
No-AA, the GPIIIa No-a1a1 or the combination of 
both, double the risk of MACE in the follow up of 
25% of our patients.
Limitations of the study
The limitations of our study are the lack of data 
on ACE and angiotensin II activity and the una-
Table 6. Cox proportional hazards to assess the effect of multiple covariates on survival.
Parameters Sig. Relative risk 95% confidence interval
Inferior Superior
Age 0.023 1.018 1.002 1.033
Family history (yes vs. no) 0.016 1.747 1.110 2.752
Diabetes mellitus (yes vs. no) 0.060 1.465 0.984 2.180
ACE (DD vs. No-DD) 0.028 1.561 1.048 2.326
ACE-AT1R (DD/No-AA vs. rest) 0.005 1.960 1.230 3.123
ACE-GPIIIa (DD/No-a1a1 vs. rest) 0.005 2.086 1.248 3.487
Patients with DD plus 1 or 2 unfavorable  
genotypes vs. the rest of the patients
0.002 1.978 1.286 3.043
ACE — angiotensin-I converting enzyme; AT1R — angiotensin II type 1 receptor; GPIIIa — platelet glycoprotein IIIa; Sig. — significant
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wareness if the patient was under ACE-inhibitors 
or sartans at hospital discharge which might have 
enabled us to establish stronger correlations of the 
studied genotypes with the clinical outcome. Also 
the recruitment of patients with MI at discharge 
may have led to a selection bias since highest-risk 
patients that had died during hospital stay were not 
included in the study.
Conclusions
We can conclude that the pathogenesis of 
MI is complex because the genetic risk profile is 
heterogeneous, due to the involvement of many 
low-penetrant candidate genes, and because envi-
ronmental and cardiovascular risk factors may in-
fluence the prognosis. However, screening patients 
for the studied polymorphisms may be useful for 
a secondary prevention strategy due to the known 
implication of RAAS, anticoagulation and platelet 
anti-aggregation therapy in the relapse of new 
coronary events.
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